eISSN 2508-3589
pISSN 2508-1926

Table. 2.

Table. 2.

The changes of best corrected visual acuity in the bevacizumab group and dexamethasone group

Baseline 1 month 2 months 3 months 4 months 5 months 6 months
BVZ 0.38 ± 0.17 0.26 ± 0.19 0.24 ± 0.12 0.31 ± 0.19 0.29 ± 0.20 0.26 ± 0.12 0.34 ± 0.19
p-value* - 0.014 0.019 0.307 0.091 0.027 0.513
DEX 0.41 ± 0.24 0.29 ± 0.08 0.25 ± 0.10 0.31 ± 0.18 0.35 ± 0.25 0.28 ± 0.19 0.20 ± 0.17
p-value* - 0.049 0.011 0.185 0.417 0.032 0.008
p-value 0.572 0.608 0.915 1 0.157 0.746 0.052

Mean change in best-corrected visual acuity (BCVA) from baseline during the follow-up period. There were no significant differences between groups at each visit. Values are presented as mean ± standard deviation.

BVZ = bevacizumab group; DEX = dexamethasone implant group.

Wilcoxon signed rank test vs. baseline;

Mann whitney U test.

J Retin 2019;4:84-92 https://doi.org/10.21561/jor.2019.4.2.84
© 2019 J Retin